MultiCell Technologies, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc.

MCET 0.000001000

-90.0%

Jun 6 1:41 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jimpit	5/16/2012 11:45:59 AM
	of 237

MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models Source: PR Newswire 08:00 ET "WOONSOCKET, R.I., May 16, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012 (http://meeting.cimt.eu), Europe's largest meeting dedicated to cancer immunotherapy research and development. CIMT 2012 will be held in May 23-25 in Mainz, Germany. The title of the poster presentation is: "Sharply discordant biological properties of synthetic noncoding dsRNA of different size: Translational opportunities in cancer." The poster presentation in the Enhancing Immunity session of the conference (poster number 078) will be made by Dr. Simona Bot, a consultant to the Company. The Company will present its findings during Poster Session I held on May 23rd, from 3:00-4:30 PM, and Poster Session II held on May 24th from 4:00-5:30 PM. "About MCT-465 and MCT-485 "MCT-465 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented TLR3 signaling technology. MCT-465 and MCT 485 are in preclinical development, and are being investigated as prospective treatments for primary liver cancer and triple negative breast cancer..." (more) (more) prnewswire.com ______________________________________________________________ Jim .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next